13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp

Stifel Financial Corp purchased a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 13,129 shares of the company’s stock, valued at approximately $43,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blair William & Co. IL raised its stake in Inhibikase Therapeutics by 7.0% during the fourth quarter. Blair William & Co. IL now owns 134,953 shares of the company’s stock worth $439,000 after purchasing an additional 8,833 shares during the period. Geode Capital Management LLC grew its holdings in Inhibikase Therapeutics by 544.9% during the 4th quarter. Geode Capital Management LLC now owns 322,878 shares of the company’s stock worth $1,049,000 after acquiring an additional 272,813 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Inhibikase Therapeutics during the 4th quarter worth approximately $16,585,000. Finally, Barclays PLC acquired a new position in Inhibikase Therapeutics during the 4th quarter worth approximately $273,000. 3.81% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Inhibikase Therapeutics in a report on Friday, March 28th.

Inhibikase Therapeutics Trading Down 1.0%

Shares of Inhibikase Therapeutics stock opened at $2.01 on Friday. The company has a fifty day simple moving average of $2.11 and a 200-day simple moving average of $2.50. Inhibikase Therapeutics, Inc. has a 12-month low of $1.12 and a 12-month high of $4.20. The stock has a market cap of $149.43 million, a price-to-earnings ratio of -0.75 and a beta of 1.01.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.